Nivo endogenog testosterona i njegova korelacija sa lipidnim profilom kod muškaraca sa akutnim infarktom miokarda, starijih od 40 godina
Sažetak
Uvod/Cilj. Uticaj lipidnog profila na akutni infarkt miokarda (AIM) dobro je poznat. Nasuprot tome, uloga nivoa endogenog testosterona (T), kao jednog od mogućih prediktivnih faktora AIM i njegovo dejstvo na lipidni profil kod muškaraca sa AIM i dalje su kontroverzni. Cilj studije je bio da se odredi nivo endogenog T u AIM, kao i 6 meseci nakon AIM kod iste grupe ispitanika i da se uporedi sa nivoima T kod zdravih ispitanika. Pored toga, određena je i korelacija nivoa T sa parametrima lipidnog profila u AIM kao i šest meseci nakon AIM. Metode. Sprovedena je prospektivna studija u koju su bili uključeni muškarci podeljeni u tri grupe: grupu I činilo je 35 muškaraca, starosne dobi 55 ± 3 godine sa AIM; grupu II sačinjavalo je istih 35 muškaraca koji su analizirani 6 meseci nakon AIM, dok se grupa III sastojala od 20 zdravih ispitanika starosne dobi 57 ± 2,12 godina. Uzorci krvi kod ispitanika grupe I uzimani su u periodu od 12h od nastanka AIM. Kod istih ispitanika krv za analize uzeta je šest mesci nakon preležanog AIM (grupa II). U krvi su određivani nivoi: ukupnog holesterola, triglicerida, lipoproteina male gustine (LDL) holesterola, lipoproteina velike gustine (HDL) holesterola, apolioporoteina A1 (Apo A1), apolipoproteina B (Apo B), lipoproteina(a) [Lp(a)] i nivo endogenog T. Rezultati. Nivo T kod ispitanika sa AIM (grupa I) (16,86 ± 7,18 nmol/L), kao i kod istih ispitanika šest meseci nakon AIM (grupa II) (18,12 ± 7,96 nmol/L) bio je statistički značajno niži u odnosu na zdravu kontrolnu grupu iste starosti (27,11 ± 10,48 nmol/L) (p < 0,001). U grupi I dobijena je statistčki značajna, pozitivna korelacija između nivoa T i HDL holesterola (r = 0.403, p < 0,05) i visoko statistički značajna, pozitivna korelacija između nivoa T i Apo A1(r = 0,747, p < 0,01). U grupi II, takođe je nađena statistički značajna pozitivna korelacija između nivoa T i HDL holeserola (r = 0,388, p < 0,05), kao i nivoa T i Apo A1 (r = 0,354, p < 0,05). Zaključak. Ova studija je pokazala da su nivoi T kod mušaraca starijih od 40 godina sa AIM visoko stistički značajno niži u odnosu na nivoe T kod zdravih muškaraca iste životne dobi. Nivoi T kod ispitanika sa AIM zadržavaju statistički značajno niže vrednosti i šest meseci nakon AIM u poređenju sa zdravom kontrolnom grupom.
Reference
Von Eckardstein A. Androgens, cardiovascular risk factors, and atherosclerosis. In: Nieschlag E, Behre HM, editors. Testos-terone: Action, Deficiency, Substitution. 2nd ed. Berlin, Hei-delberg New: Springer; 1998. pp. 229–58.
Godsland IF. Cnages in metabolic inflammatory and endotheli-al indices of carsiovascularrisk. In: Lunenfeld B, Gooren L, edi-tors. Textbook of Men’s Health. New York, NY: Partenon Publishing Group; 2002. p. 317–8.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–52.
Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26(3): 210–2.
Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipo-proteins, and atherosclerosis: prevailing assumptions and out-standing questions. Am Heart J 1987; 114(6): 1467–503.
Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk 1997; 4(5–6): 363–6.
Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improve-ment in the prediction of fatal myocardial infarction (AMO-RIS study): a prospective study. Lancet 2001; 358(9298): 2026–33.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–52.
Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial in-farction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26(3): 271–8.
Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: hu-man apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1(3): 256–9.
Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Inter-action of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991; 87(3): 767–71.
von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipopro-tein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37(2): 434–9.
Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endog-enous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88(11): 5076–86.
Christou GA, Christou KA, Nikas DN, Goudevenos JA. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. Eur J Prev Cardiol 2016; 23(16): 1785–96.
Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: A case-crossover analysis. Clin Endocrinol (Oxf) 2018; 88(5): 719–27.
Li H, Mitchell L, Zhang X, Heiselman D, Motsko S. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hy-pogonadal Men: An Administrative Health Care Claims Study. J Sex Med 2017; 14(11): 1307–17.
Cheetham TC, An J, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, et al. Association of Testosterone Replacement With Cardio-vascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med 2017; 177(4): 491–9.
Fortunati N. Sex hormone-binding globulin: not only a transport protein. What news is around the corner? J Endo-crinol Invest 1999; 22(3): 223–34.
Duell PB, Bierman EL. The relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men. Arch Intern Med 1990; 150(11): 2317–20.
Page ST, Mohr BA, Link CL, O'Donnell AB, Bremner WJ, McKinlay JB. Higher testosterone levels are associated with in-creased high-density lipoprotein cholesterol in men with car-diovascular disease: results from the Massachusetts Male Aging Study. Asian J Androl 2008; 10(2): 193–200.
Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77(6): 1610–5.
Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J. Low serum tes-tosterone in men is inversely associated with non-fasting se-rum triglycerides: the Tromsø study. Nutr Metab Cardiovasc Dis 2008; 18(4): 256–62.
Hämäläinen E, Adlercreutz H, Ehnholm C, Puska P. Relation-ships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 1986; 35(6): 535–41.
Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10(2): 240–5.
Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for li-pid-modifying therapy. J Intern Med 2004; 255(2): 188–205.
Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cho-lesterol ratios to estimate the balance between plasma proath-erogenic and antiatherogenic lipoproteins and to predict coro-nary risk. Clin Chem Lab Med 2004; 42(12): 1355–63.
Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the meta-bolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35(10): 2248–52.
Liting P, Guoping L, Zhenyue C. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients. Herz 2015; 40 Suppl 1: 1–7.
Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Rancho Bernardo Study. Endogenous sex hormones and the develop-ment of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25(1): 55–60.
Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102(2): 151–66.
Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Vis-ceral fat accumulation in men is positively associated with in-sulin, glucose, and C-peptide levels, but negatively with tes-tosterone levels. Metabolism 1990; 39(9): 897–901.
Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Interven-tion Trial participants. Am J Epidemiol 1997; 146(8): 609–17.
Haffner SM. Androgens in relation to cardiovascular disease and insulin resistend in aging male. In: Oddens BJ, Vermeulen A, editors. Androgens and the aging male. New York: The Parthenon Publishing Group; 1996. p. 68–72.
Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen SU. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982; 54(6): 1113–7.